Clinical Trial Data Reporting: what's changed?

With the pandemic, regulators are looking for an expanded list of items when it comes to clinical data reporting.  Nutrasource's VP of NHP and Pharmaceutical Sciences, Tania John, sums it up nicely in the below video. 

Additionally, learn from Amy Mozingo, Nutrasource's VP of US Nutra Regulatory Sciences as she provides insight into the US regulatory landscape for food and dietary supplements since COVID-19 and why the FDA has actively been handing out warning letters.